百时美施贵宝公司（Bristol Myers Squibb Co.）用于治疗一种罕见内分泌癌和一种致命肺部疾病的实验药物在后期研究中取得成功，提升了该制药公司的新产品管线。
Bristol Myers Squibb Co.’s experimental drugs for treating a rare endocrine cancer and a deadly form of lung disease succeeded in late-stage studies, boosting the pharmaceutical company’s new product pipeline.
公司表示，患有特发性肺纤维化（一种会导致肺部瘢痕、使血液难以获得足够氧气的慢性病）的患者在服用该公司名为admilparant的药片低剂量后，呼吸功能显著改善。该研究是新药获批前所需的第三阶段及最终阶段测试。
The company said patients with idiopathic pulmonary fibrosis, a chronic condition that scars the lungs and makes it difficult to get oxygen into the bloodstream, had their breathing significantly improve after getting a lower dose of the company’s pill, called admilparant. The study was from the third and final phase of testing required before a new drug approval.
对患有胃肠胰腺神经内分泌肿瘤（一种起源于胃肠道或胰腺内分泌细胞的罕见癌症）患者的后期研究进行计划中的中期分析发现，公司的RYZ101药物显著减缓了疾病进展。
A planned interim analysis of a late-stage study in patients with gastroenteropancreatic neuroendocrine tumors, a rare type of cancer that starts in the endocrine cells of the gastrointestinal tract or the pancreas, found the company’s RYZ101 significantly slowed progression of the disease.
百时美施贵宝股价在纽约市场周一开盘前的早盘交易中一度上涨7.5%。
Bristol Myers shares gained as much as 7.5% in early trading before markets opened Monday in New York.